New pill CT-996 tested for obesity and diabetes – early results promising?
NCT ID NCT05814107
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This early-stage trial tested a new drug called CT-996 in 94 overweight or obese adults, including some with type 2 diabetes. The main goal was to check safety and how the body processes the drug. Researchers gave single or multiple doses and monitored side effects. This is a first step to see if the drug might help with weight and blood sugar, but much more research is needed.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CT-996 (a drug capsule)
What this could lead to
If successful, this could point toward a new oral medication for weight management and blood sugar control in type 2 diabetes.
What could go wrong
This is a very early Phase 1 trial focused on safety, not effectiveness. The drug may not work as hoped or could have side effects. Results may not apply to the general population.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Avant Santé Research Center S.A. de C.V.
San Pedro Garza García, 66260, Mexico
-
Nucleus Network Pty Ltd.
Melbourne, 3004, Australia